CLRB - Cellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A Look
Our analysis concludes CLRB appears a worthwhile speculative investment at $1.15 per share primarily because the potential upside dramatically outweighs the risk of downside based on, among other things, the results of CLRB's Phase 2 trial (called CLOVER-1) of its CLR131 candidate therapy in patients with Multiple Myeloma and B-cell Lymphomas.
On September 9, 2020 CLRB reported a collective 40% ORR and longer "predicted" progression free survival than current FDA approved MM therapies. This part of the trial studied 15 patients with Triple Class Refractory Multiple Myeloma. Triple class means the subject patients refractory (did